JPET Celsis microsomes equal better data

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on June 30, 2008; DOI: 10.1124/jpet.108.139733


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.108.139733v1
327/1/168    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zeng, H.
Right arrow Articles by Xu, X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zeng, H.
Right arrow Articles by Xu, X.


Received for publication April 8, 2008.
Revised June 25, 2008.
Accepted for publication June 26, 2008.

1-[1-hexyl-6-(methyloxy)-1H-indazol-3-yl]-2-methyl-1-propanone (HMIMP), a Potent and Highly Selective Small Molecule Blocker of the Large-Conductance Voltage-gated and Calcium-dependent K+ Channel

Haoyu Zeng 1, Earl A. Gordon 2, Zuojun Lin 2, Irina M. Lozinskaya 2, Robert N. Willette 2, Xiaoping Xu 2*

1 Merck Research Laboratories 2 GlaxoSmithKline

* Address correspondence to: E-mail: xiaoping.2.xu{at}gsk.com

Abstract

The large-conductance voltage-gated and calcium-dependent K+ (BK) channels are widely distributed and play important physiological roles. Commonly used BK channel inhibitors are peptide toxins isolated from scorpion venoms. A high-affinity, non-peptide, synthesized BK channel blocker with selectivity against other ion channels has not been reported. We prepared several compounds from a published patent application (Doherty, et al., 2004) and identified 1-[1-hexyl-6-(methyloxy)-1H-indazol-3-yl]-2-methyl-1-propanone (HMIMP) as a potent and selective BK channel blocker. The patch-clamp technique was used for characterizing the activity of HMIMP on recombinant human BK channels ({alpha} subunit, {alpha}+{beta}1 and {alpha}+{beta}4 subunits). HMIMP blocked all these channels with an IC50 of ~2 nM. The inhibitory effect of HMIMP was not voltage-dependent, nor did it require opening of BK channels. HMIMP also potently blocked BK channels in freshly isolated detrusor smooth muscle cells and vagal neurons. HMIMP (10 nM) reduced the open probability significantly without affecting single BK channel current in inside-out patches. HMIMP did not change the time constant of open states but increased the time constants of the closed states. More importantly, HMIMP was highly selective for the BK channel. HMIMP had no effect on human NaV1.5 (1 µM), CaV3.2, L-type Ca2+, hERG, KCNQ1+minK, transient outward K+ or voltage-dependent K+ channels (100 nM). HMIMP did not change the action potentials of ventricular myocytes, confirming its lack of effect on cardiac ion channels. In summary, HMIMP is a highly potent and selective BK channel blocker which can serve as an important tool in the pharmacological study of the BK channel.


Key words: calcium channel, channel blocker, potassium channel, single channel, sodium channel, voltage-gated ion channel





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.